MRGPRX4 mediates phospho-drug–associated pruritus in a humanized mouse model

Daphne Chun-Che Chien,Nathachit Limjunyawong,Can Cao,James Meixiong,Qi Peng,Cheng-Ying Ho,Jonathan F. Fay,Bryan L. Roth,Xinzhong Dong
DOI: https://doi.org/10.1126/scitranslmed.adk8198
IF: 17.1
2024-05-10
Science Translational Medicine
Abstract:The phosphate modification of drugs is a common chemical strategy to increase solubility and allow for parenteral administration. Unfortunately, phosphate modifications often elicit treatment- or dose-limiting pruritus through an unknown mechanism. Using unbiased high-throughput drug screens, we identified the Mas-related G protein–coupled receptor X4 (MRGPRX4), a primate-specific, sensory neuron receptor previously implicated in itch, as a potential target for phosphate-modified compounds. Using both G q -mediated calcium mobilization and G protein–independent GPCR assays, we found that phosphate-modified compounds potently activate MRGPRX4. Furthermore, a humanized mouse model expressing MRGPRX4 in sensory neurons exhibited robust phosphomonoester prodrug–evoked itch. To characterize and confirm this interaction, we further determined the structure of MRGPRX4 in complex with a phosphate-modified drug through single-particle cryo–electron microscopy (cryo-EM) and identified critical amino acid residues responsible for the binding of the phosphate group. Together, these findings explain how phosphorylated drugs can elicit treatment-limiting itch and identify MRGPRX4 as a potential therapeutic target to suppress itch and to guide future drug design.
cell biology,medicine, research & experimental
What problem does this paper attempt to address?